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Invasive meningococcal disease (IMD) represents a public health 
problem and a leading cause of morbidity and mortality worldwide. 
IMD can occur as an endemic disease with sporadic cases or epi-
demics with outbreaks. Neisseria meningitis strains are divided into 
13 serogroups, but only five (A, B, C, W-135, and Y) are respon-
sible for most IMD across the world. All age groups are at risk 
for IMD, but infants and adolescents are particularly vulnerable. 
The most common clinical manifestations of IMD are meningitis 
and septicemia, although in some cases both clinical pictures are 
present. The clinical pattern can differ according to age; in young 
children, the clinical manifestations may be more insidious and 
the diagnosis may be more difficult compared to older children 
or adolescents. Death occurs in 6-10% of cases and sequelae in 
4.3-11.2% of cases. Early recognition of children with meningo-
coccal infection is important in order to initiate systemic antibiotic 
therapy, although vaccination remains the best strategy to control 
meningococcal disease. Recently, different meningococcal vac-
cines have been introduced worldwide, resulting in a reduction in 
the overall burden of the disease. The goal of the next few years 
should be to increase vaccination coverage against meningococcal 
diseases, continue to monitor IMD and develop a unique vaccine 
able to cover all of the main meningococcal strains.
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Summary
Introduction
Neisseria meningitidis is an anaerobic Gram-negative 
diplococcus that is responsible for invasive meningo-
coccal disease (IMD), which represents a public health 
problem and a leading cause of morbidity and mortal-
ity worldwide [1, 2]. Globally, the incidence of IMD is 
500,000 cases every year, although the incidence varies 
from <1 per 100,000 per year in North America and Eu-
rope to 10-1,000 per 100,000 per year in the “meningi-
tis belt” of sub-Saharan Africa [3, 4]. Death occurs in 
6-10% of cases and sequelae in 4.3-11.2% of cases [5]. 
Meningococcal carriage, which represents the first step 
of disease transmission, varies with age and setting. It 
is known that N. meningitidis colonizes the nasophar-
ynx in up to 5-10% of adults who are asymptomatic. A 
recent study demonstrated that the carriage prevalence 
increases throughout childhood from 4.5% in infants to 
a peak of 23.7% in 19 year old subjects, then decreases 
to 7.8% in 50 year old adults [6]. This overview summa-
rizes new data on meningococcal disease in children and 
the possibilities of its prevention.
Epidemiology
N. meningitidis strains are divided into 13 serogroups on 
the basis of the immunochemistry of their capsular polysac-
charides; however, only five serogroups (A, B, C, W-135, 
Y, and X) are responsible for most IMD cases around the 
world [4]. IMD can occur as an endemic disease with spo-
radic cases or epidemics with outbreaks. All age groups are 
at risk for IMD, but infants and adolescents are particularly 
vulnerable due to the disappearance of maternal antibodies 
early in life and the high rate of nasopharyngeal coloniza-
tion [2, 3]. Some settings, such as schools, university dor-
mitories and barracks, are at high risk for N. meningitidis 
transmission. Moreover, low socioeconomic status, minor-
ity ethnicity, immune deficiencies and asplenia predispose 
individuals to meningococcal infection [2, 3]. 
The serogroups causing IMD vary geographically, 
mostly likely due to differences in population immunity 
and environmental factors. Meningococcus serogroup A 
(MenA) occurs in Africa and some areas of Asia, where-
as serogroups B (MenB), C (MenC) and Y (MenY) are 
predominant in the other continents, including Europe 
and North America [2, 4]. In the 13 countries included in 
the African “meningitis belt”, MenA was responsible for 
the majority of cases in 2007-2009, while meningococ-
cus serogroup W135 (MenW135) predominated in 2010 
and 2011 [4]. Although MenC is rare in Africa, in 2013 
and 2014 two outbreaks due to a novel strain of MenC 
were reported in Nigeria and Kebbi, respectively [7]. 
Moreover, during 2006-2010 outbreaks of MenX were 
described in Niger, Togo, Kenya, Uganda, and Burkina 
Faso [8]. In Europe, MenB is the main cause of IMD, 
followed by MenC and MenY [4]. In countries with es-
tablished MenC vaccination programs, the incidence of 
MenC disease has significantly declined [2, 4]. In com-
parison with the US, IMD caused by MenY is rare in 
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Europe. However, an increase in this serogroup has been 
reported in recent years, particularly in the Nordic Euro-
pean countries [9]. 
Clinical manifestation and sequelae
The most common clinical manifestations of meningo-
coccal infection are meningitis and septicemia, although 
in some cases both clinical pictures are present [3, 10-12]. 
However, signs and symptoms at the onset of the dis-
ease, such as coryza and sore throat, may resemble those 
of common respiratory viral infections [11]. The incuba-
tion period varies from 1 to 14 days, although it usually 
lasts less than 2 days [11]. 
The clinical pattern can differ according to age, and it is not 
infrequent for children to be initially misdiagnosed. The 
clinical manifestations may be more insidious in young 
children, with non-specific signs; thus, diagnosis may be 
more difficult than in older children or adolescents. Irrita-
bility and lethargy are common features at this age. In some 
cases, seizures with focal onset may occur at the beginning 
of the disease. Moreover, neck stiffness is rare in children 
younger than 2 years of age [3, 10-12]. Bulging anterior 
fontanalle may occur in infants <18 months of age. In gen-
eral, infants exhibit a more rapid progression of the disease 
compared to older children [12]. Similar to adults, in older 
children the most common symptoms are fever, nausea, 
vomiting, photophobia, headache, agitation, decreased lev-
el of consciousness and neck stiffness. However, seizure 
and focal neurological signs are less common [3, 10-12]. 
Septic shock is more common in children and progresses 
rapidly, with multiple organ failure and death occurring 
within 24 hours [3, 10-12]. Often, non-specific symptoms 
such as fever, drowsiness, nausea and vomiting, irritabil-
ity and poor feeding are present within 4-6 hours from the 
onset of the disease [3, 10-12]. One of the most common 
symptoms associated with sepsis is a rapidly progressive 
hemorrhagic rash that usually starts on the lower extremi-
ties, although mucous membranes and sclera may be in-
volved [3, 10-12]. Skin lesions include macules, maculo-
papules, urticaria, petechiae, purpura and ecchymoses. The 
purpuric rash may progress to purpura fulminans, a cuta-
neous manifestation of disseminated intravascular coagu-
lation. These cases are often associated with septic shock 
and skin necrosis, ischemia, or infarction of digits or limbs 
that usually require amputation [3, 10-12]. Three clinical 
signs of early sepsis have been identified in children and 
adolescents: leg pain, cold hands and feet, and abnormal 
skin color. These features may suggest that the vital signs 
are compromised  [11]. Some authors reported chronic 
meningococcemia that consisted of recurrent attacks of fe-
ver, arthralgia and/or arthritis associated with a rash and 
headache [3, 11]. 
IMD is a life-threatening disease with a very high rate of 
severe sequelae among survivors. In a recent article, Sa-
dargani et al. evaluated the outcomes of IMD in 868 sub-
jects (52% adults and 48% children) in Canada between 
2002 and 2011. The mortality was lower in children 
than in adults, but 21% of children (particularly those 
< 5 years of age) had at least one complication compared 
with 15% of adults. The highest complication rates oc-
curred in children with septic shock without meningi-
tis, and the most common sequelae were hearing loss, 
deafness, seizure, amputation and skin scarring [13]. In a 
study that evaluated the outcome of IMD in 181 children 
< 15 years of age, the case fatality rate was 11.6% and 
at least one long-term sequelae was reported in 33% of 
patients: learning academic difficulties (22.6%), hearing 
impairment (7%), and neurological (12.2%), behavioral 
(14.8%) and motor (10.4%) deficits [14]. 
The duration of illness prior to admission and the pres-
ence of seizures, focal neurological deficits, depressed 
level of consciousness and low levels of cerebrospinal 
fluid glucose may be associated with a high risk of se-
quelae [11]. Wang at al. demonstrated that sequelae oc-
curred in all children <1 years of age with IMD and a 
history of prematurity [15]. 
Treatment
Due to the severity of meningococcal disease includ-
ing its high case fatality rate and possibility of sequelae, 
early clinical and laboratory diagnosis is very important. 
Lumbar puncture must be performed in all suspected 
cases with clinical signs and symptoms of IMD. In most 
cases, cerebrospinal fluid (CSF) reveals high opening 
pressure, pleocytosis, high protein levels and low glu-
cose levels [10]. N. meningitidis should be detected in 
the CSF or blood by Gram staining, standard culture 
and/or polymerase chain reaction (PCR) [10, 11]. These 
examinations must be performed very quickly to avoid 
delays in the administration of therapy. Sometimes 
standard cultures may result in false negatives due to 
prior administration of oral antibiotic treatment that re-
duces the sensitivity of the exam. In these cases, PCR 
could be useful [10]. Lumbar puncture can be hazardous 
in patients with prolonged seizures, immunocompro-
mised patients, in the presence of signs of space-occu-
pying lesions and in patients with severe impairment of 
consciousness and shock [10]. 
Prompt and adequate intravenous antibiotic treatment is 
essential to stop the proliferation and kill N. meningitidis. 
Local antibiotic resistance should guide the choice of the 
antibiotic. In most cases, an intravenous third-generation 
cephalosporin (e.g., 100 mg/kg/day ceftriaxone adminis-
tered i.v. in one daily dose or 100 mg/kg/day cefotaxime 
administered i.v. divided into three daily doses) should be 
used as the first choice of treatment. If these antibiotics 
are not available, intravenous penicillin should be start-
ed  [10, 11]. If available, the result of antibiotic sensitivi-
ties could guide the continuation of the antibiotic therapy. 
The recommended duration of treatment is 7-10 days, al-
though recent studies demonstrated that CSF sterilization 
may occur within 3-4 days [10, 11]. 
Prophylaxis is indicated and recommended only for 
close contacts of the index case (i.e., subjects who re-
mained with the index case for more than 4 hours dur-
ing the 7 previous days). In these cases, oral rifampicin 
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or ciprofloxacin are the drugs of choice according to 
age [11]. 
Meningococcal vaccines
Vaccination remains the best strategy to prevent menin-
gococcal disease due to the high fatality rate and the sig-
nificant sequelae that can result from the infection despite 
prompt antibiotic treatment. Recently, new meningococ-
cal vaccines have been introduced worldwide, resulting in 
a reduction in the overall burden of the disease. 
Since the introduction of the meningococcal serogroup 
C conjugate vaccine, the incidence of MenC disease 
has significantly declined [16]. Commercially avail-
able monovalent conjugate vaccines include Menjugate 
(MCC-CRM197), Meningitec (MCC-CRM197) and 
NeisVac (MCC-TT). Quadrivalent vaccines contain-
ing the meningococcal ACWY serogroups conjugated 
with different proteins have also been produced. Those 
available in the market are Menactra (ACWY-DT) li-
censed for children aged 2-55 years, Menveo (ACWY-
CRM197) licensed in Europe and the US for children 
≥2 years of age and Nimenrix (ACWY-TT) licensed in 
Europe for infants ≥12 months of age. These conjugated 
vaccines have proven to be safe and effective in protect-
ing individuals against meningitis; moreover, these vac-
cines have demonstrated herd immunity by interrupting 
carriage transmission [17-19]. The quadrivalent poly-
saccharide vaccines Menomune and Mencevax have 
also proven to be safe and elicit bactericidal antibodies 
in older children and adults; however, they are not used 
in routine vaccination programs due to their poor im-
munogenicity in young children, short-term protection 
and inability to produce herd immunity [16, 18]. Unfor-
tunately, quadrivalent ACYW meningococcal vaccines 
(conjugated or polysaccharide) are not widely used in 
developing countries due to high costs. An effective and 
safe conjugate vaccine against MenA (MenAfrivac) first 
licensed in India in 2009 was introduced into the Afri-
can “meningitis belt” in 2010 for subjects between 1-29 
years of age; this vaccine is being implemented in these 
regions with the goal of protecting the entire population 
at risk by the year 2016 [18]. 
Considering the high incidence of MenB disease in de-
veloped countries, the production of a vaccine effective 
against this serotype was a priority. However, vaccines 
against MenB were difficult to produce. Because the ex-
ternal polysaccharide capsule of MenB resembles the ad-
hesion molecules on the surface of neural cells, conjugate 
vaccines were not protective against MenB disease and 
moreover could induce an autoimmune response [5, 20]. 
The first vaccine that showed a partial efficacy against 
MenB disease was produced in Cuba, New Zealand and 
Norway, but it was strain specific and therefore was used 
only to control the epidemics [5]. For these reasons, this 
vaccine could not be considered effective against the 
different MenB strains that cause epidemics worldwide. 
After several attempts, a multicomponent MenB vaccine 
(4CMenB, Bexsero) that covered different strains was 
produced using reverse vaccinology [5, 21]. 4CMenB 
was composed of four components: the first component 
was the factor H binding protein (fHbp) fused with the 
GNA 2091 protein, the second was Neisseria adhesion 
A (NadA), the third was the Neisseria heparin binding 
protein (NHba) fused with the GNA 1030 protein, and 
the forth component was OMV NZ98/254, which has 
several antigen components (the major component is 
PorA). The three antigens fHbp, NadA and NHba evoke 
serum bactericidal antibodies, while the two antigens 
GNA 2091 and GNA 1030 improve the immunogenicity 
of the major antigens when fused with them [5, 20]. In 
January 2013, 4CMenB was licensed in the European 
Union and thereafter in Australia and Canada for use in 
subjects older than 2 months of age [5, 20]. Considering 
the low incidence of IMD, it is quite difficult to evaluate 
the impact of any meningococcal vaccine through ran-
domized controlled clinical studies. Although serologi-
cal methods could be used to evaluate the protection of 
other meningococcal vaccines, these methods could not 
be used for 4CMenB due to the high number of geneti-
cally different MenB strains that cause IMD. To over-
come this problem, the vaccine’s manufacturer used a 
new method called the meningococcal antigen typing 
system (MATS) that uses a unique vaccine antigen-spe-
cific ELISA capable of detecting qualitative and quan-
titative differences in the fHbp, NHba, and NadA anti-
gens; then, the results are combined with PorA typing 
information [5]. The results from the analysis of 1,052 
MenB strains isolated from different countries in Europe 
showed that 4CMenB could protect against 68%-88% of 
MenB strains [5]. A bivalent fHbp recombinant vaccine 
(also known as LP2086; Trumenba) has been developed 
since 2006 and has now been approved by the US Food 
and Drug Administration for use in 10- to 25-year olds 
[26]. This vaccine appeared to be safe in a phase 3 study 
in approximately 5,600 healthy individuals aged 10 
through 25 years and was immunogenic and safe when 
co-administered with routine meningococcal A, C, Y, 
and W and tetanus, diphtheria and pertussis (Tdap) vac-
cines in a phase 2 study in more than 2,600 healthy in-
dividuals aged 10 through 12 years [26]. Studies on this 
vaccine are ongoing in Europe, and approval from the 
European Medicines Agency is expected in 2017. 
In the future, optimal preventive strategies necessitate a 
unique vaccine against MenA, B, C, W, and Y. A recent 
phase 2 study assessed the immunogenicity, safety and 
reactogenicity in healthy adolescents of an investiga-
tional formulation of a meningococcal ABCWY vaccine 
consisting of recombinant proteins (rMenB) and OMV 
components of a licensed serogroup B vaccine combined 
with components of a licensed quadrivalent meningo-
coccal conjugate vaccine (MenACWY-CRM) [23]. The 
authors showed that the investigational MenABCWY 
formulation containing OMV components elicited a 
high response against all strains with an acceptable safe-
ty profile [23]. 
Due to the emergence of MenX in Africa in the last dec-
ades, it is extremely important to develop a new vaccine 
that is effective against this serotype. No licensed vaccine 
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is available at present, but interesting data were reported 
in a recent study conducted in mice that evaluated the im-
munogenicity of the MenX outer membrane vesicles (X-
OMV) or MenX polysaccharide (X-PS) combined with a 
bivalent AW-OMV vaccine previously demonstrated to 
be immunogenic in mice [24]. The authors demonstrated 
that a high antibody response was induced after two doses 
of X-OMV alone or combined with AW-OMV. In con-
trast, X-PS was not immunogenic alone but was immuno-
genic in combination with AW-OMV.
Conclusions
IMD represents a severe and life-threatening problem for 
the worldwide community. Early recognition of children 
with meningococcal infection is mandatory in order to 
immediately start systemic antibiotic therapy and avoid 
death or long-term sequelae. Vaccination represents the 
best strategy to prevent meningococcal disease. Recent-
ly, the introduction of new conjugate vaccines that are ef-
fective in very young children has significantly reduced 
the incidence of IMD in many countries. Moreover, the 
availability of new vaccines against MenB will permit a 
further increase in preventive possibilities against IMD. 
The goal of the next few years should be to increase vac-
cination coverage against meningococcal diseases, con-
tinue to monitor IMD and develop a unique vaccine able 
to cover all of the main meningococcal strains. 
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